Octapharma USA Launches Co-Pay Assistance Program for Patients Receiving wilate

On Feb 2, 2015

Hoboken-based Octapharma USA today announced a new financial support program for the bleeding disorders community. The Octapharma Co-Pay Assistance Program is available to von Willebrand’s Disease (VWD) patients who are currently receiving wilate  [von Willebrand Factor/Coagulation Factor VIII Complex (Human)] or have a prescription to begin therapy.

The new program offers eligible patients a maximum of $6,000 annually for co-pay, co-insurance and deductible expenses associated with their treatment without regard for their ability to pay. Patients must have third-party commercial insurance to participate in the program.

“We realize that patient out-of-pocket expenses associated with healthcare can sometimes be daunting, therefore, Octapharma has committed to support a program specifically designed to supplement these costs,” said Octapharma USA President Flemming Nielsen. “Octapharma is focused on creating support programs that adapt to meet patient needs and ensure continued access to therapies recommended by their medical providers. Coupled with ongoing educational programs, these efforts emphasize our strong belief that patient needs must always come first.”

The program is not available to patients who are covered under Medicaid, Medicare, MediGap, VA, DOD, TRICARE or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program. Participants must be residents of the United States.

Related Articles: